Mitchell AP.
In the companion to this article, Jeong et al present new findings regarding the use of charity assistance among patients beginning treatment with abiraterone acetate or enzalutamide. Their primary findings—one third of patients with prostate cancer require charity assistance to afford these medications—highlight the adverse consequences for patients resulting from the high cost of cancer drugs, particularly those with Medicare Part D as their primary drug benefit. This study provides additional support for calls to reform the Part D benefit structure to improve the affordability of cancer drugs.
